Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

€7.4bn ‘Just The Start’ For Global COVID-19 Drug & Vaccine Funding Project

Challenges Huge, Calls For IP On Coronavirus Tools To Be Pooled

Executive Summary

It’s not enough just to develop new drugs and vaccines for COVID-19. These tools must be made available to all those who need them wherever they are; for this to happen, health systems will need to be strengthened, say the backers of an EU-led funding initiative. Industry says it has already brought considerable resources to the table and stresses that close international cooperation will be vital if the pandemic is to be tackled effectively.

You may also be interested in...



WHO Launches Global Push For Tools To Tackle COVID-19

A global collaboration initiative launched by the World Health Organization is intended to foster the development of COVID-19 vaccines, medicines and diagnostics and to make sure they reach all those who need them. 

UK/EU Industry ‘Still Working In The Dark’ On Post-Brexit Regulation

As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.

EU Politicians Squeeze Pharma Execs On Coronavirus Vaccine Contracts

With coronavirus cases again on the rise in many European countries, members of two EU parliamentary committees asked industry representatives to explain why details of COVID-19 vaccine supply agreements are being kept under wraps.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel